Literature DB >> 1175861

Insulin metabolism in hypothyroidism.

J H Shah, G S Motto, E Papagiannes, G A Williams.   

Abstract

Insulin resistance has been invoked to explain the glucose intolerance observed in hypothyroid patients. This possibility was studied by determining fractional and metabolic clearances of intravenously administered porcine crystalline insulin (0.1 U./kg.) and its effect on plasma glucose concentration in ten hypothyroid patients, ten normal subjects, and six treated euthyroid patients. Following administration of porcine insulin, serum immunoreactive insulin concentrations during the period of observation were similar in hypothyroid patients, in normal control subjects, and in treated euthyroid patients. Similarly, no significant differences in the mean half-life, distribution space, or fractional and metabolic clearances of insulin were observed among any of the three groups. In response to insulin administration, plasma glucose concentrations declined to the nadir of 36 +/- 4, 43 +/- 3, and 38 +/- 4 mg. per 100 ml. in hypothyroid patients, normal control subjects, and treated euthyroid patients, respectively. Thereafter, plasma glucose steadily increased and approached the baseline value at ninety minutes in normal subjects and treated euthyroid patients. In contrast, the plasma glucose values remained significantly lower than the baseline for the rest of the procedure in hypothyroid patients. The present study demonstrates that there is no evidence of resistance to the action of insulin in hypothyroid patients. The observation of prolonged hypoglycemic action of exogenously administered insulin in hypothyroid patients might in fact suggest increased sensitivity to insulin action. These findings indicate that glucose intolerance of the hypothyroid state is not characterized by insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1175861     DOI: 10.2337/diab.24.10.922

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  IS BETA CELL DYSFUNCTION RESPONSIBLE FOR FLAT GLUCOSE TOLERANCE CURVE IN PRIMARY HYPOTHYROIDISM? (A HYPOTHESIS).

Authors:  R Pakhetra; M K Garg; J S Saini
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 3.  Thyroid hormone action on intermediary metabolism. Part I: respiration, thermogenesis and carbohydrate metabolism.

Authors:  M J Müller; H J Seitz
Journal:  Klin Wochenschr       Date:  1984-01-02

4.  The metabolic syndrome in thyroid disease: A report from Nigeria.

Authors:  Anthonia O Ogbera; Sonny Kuku; Olusola Dada
Journal:  Indian J Endocrinol Metab       Date:  2012-05

5.  Autoimmune thyroiditis as a risk factor for stroke: a historical cohort study.

Authors:  André Karch; Sara L Thomas
Journal:  Neurology       Date:  2014-04-09       Impact factor: 9.910

6.  Protective effect of a polyherbal bioactive fraction in propylthiouracil-induced thyroid toxicity in ratsby modulation of the hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes.

Authors:  Sneha Singh; Vandana Panda; Sudhamani S; Payal Dande
Journal:  Toxicol Rep       Date:  2020-06-11

7.  Thyroid diseases increased the risk of type 2 diabetes mellitus: A nation-wide cohort study.

Authors:  Rong-Hsing Chen; Huey-Yi Chen; Kee-Ming Man; Szu-Ju Chen; Weishan Chen; Po-Len Liu; Yung-Hsiang Chen; Wen-Chi Chen
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

8.  The hypoglycemic side of hypothyroidism.

Authors:  Sanjay Kalra; Ambika Gopalakrishnan Unnikrishnan; Rakesh Sahay
Journal:  Indian J Endocrinol Metab       Date:  2014-01

9.  Risk of Depression, Chronic Morbidities, and l-Thyroxine Treatment in Hashimoto Thyroiditis in Taiwan: A Nationwide Cohort Study.

Authors:  I-Ching Lin; Hsin-Hung Chen; Su-Yin Yeh; Cheng-Li Lin; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.